11 Feb
2021

How the rise of PTAB discretionary denials impacts Hatch-Waxman strategies

The recent denial of a Mylan IPR petition suggests that some pharma patents may be insulated from controversial administrative challenges, with serious implications for generic litigation strategies

Adam Houldsworth

Author | Life sciences reporter

[email protected]

Adam Houldsworth